Celiac Disease - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 82 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Celiac Disease - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Celiac Disease - Pipeline Review, H2 2016', provides an overview of the Celiac Disease pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Celiac Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Celiac Disease
- The report reviews pipeline therapeutics for Celiac Disease by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Celiac Disease therapeutics and enlists all their major and minor projects
- The report assesses Celiac Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Celiac Disease

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Celiac Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding  Celiac Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Celiac Disease Overview 9
Therapeutics Development 10
Pipeline Products for Celiac Disease - Overview 10
Pipeline Products for Celiac Disease - Comparative Analysis 11
Celiac Disease - Therapeutics under Development by Companies 12
Celiac Disease - Therapeutics under Investigation by Universities/Institutes 14
Celiac Disease - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Celiac Disease - Products under Development by Companies 17
Celiac Disease - Products under Investigation by Universities/Institutes 18
Celiac Disease - Companies Involved in Therapeutics Development 19
Amgen Inc. 19
Amyra Biotech AG 20
Avaxia Biologics, Inc. 21
Calypso Biotech SA 22
enGene, Inc 23
F. Hoffmann-La Roche Ltd. 24
Glenmark Pharmaceuticals Ltd. 25
ImmusanT, Inc. 26
Innovate Biopharmaceuticals, Inc. 27
Intrexon Corporation 28
Sanofi 29
Zedira GmbH 30
Celiac Disease - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
AMG-714 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
AVX-176 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Biologic for Celiac Disease - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
BNZ-2 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
CALY-002 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
ERW-1041E - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
GBR-830 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
larazotide acetate - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
latiglutenase - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Central Nervous System and Oncology - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Nexvax-2 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Nexvax-3 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Oligonucleotides for Celiac Disease - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Protein for Celiac Disease - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Recombinant Enzymes for Celiac Disease - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Recombinant Protein for Celiac Disease and Type-1 Diabetes - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
RG-7625 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Synthetic Peptides to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Vaccine for Celiac Disease - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Vaccine for Celiac Disease - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
ZED-1227 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
ZED-754 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Celiac Disease - Dormant Projects 68
Celiac Disease - Product Development Milestones 69
Featured News & Press Releases 69
May 24, 2016: ImmusanT Reports Nexvax2 Phase 1 Data in Patients with Celiac Disease 69
May 19, 2016: ImmusanT Announces Presentations at Digestive Disease Week 2016 70
May 05, 2016: Celimmune Commences First-Ever Dosing with AMG 714 in Celiac Disease 71
Mar 31, 2016: Celimmune Commences Screening in Phase 2 Clinical Study in Refractory Celiac Disease Type II 72
Sep 23, 2015: Celimmune to Present Overview of Non-Dietary Celiac Disease Therapies in Development at Annual Celiac Support Association Meeting 73
Sep 03, 2015: Glenmark's Novel Monoclonal Antibody GBR 830 to Enter Phase 2 Clinical Studies in Atopic Dermatitis and Celiac Disease in US and Europe 73
Jun 22, 2015: Celimmune to Present Experimental Anti3IL315 Antibody AMG!714 at 16th International Coeliac Disease Symposium 74
Jun 22, 2015: Cour Pharmaceuticals Releases Data on Potential Breakthrough Treatment for Celiac Disease 74
Nov 19, 2014: ImmusanT's Immunotherapy for Celiac Disease, Nexvax2, Selected as One of Informa's Top 10 Autoimmune/Anti-Inflammatory Projects to Watch 75
Jun 12, 2014: Potential New Treatment May Protect Celiac Patients from Gluten-Induced Injury 76
Feb 11, 2014: Alba Therapeutics Announces Positive Results of Phase IIb Trial in Celiac Disease 76
Oct 29, 2013: Alvine Pharmaceuticals Doses First Patient in Phase 2b Trial for ALV003 in Celiac Disease 77
Aug 06, 2013: ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes 78
Apr 19, 2013: ImmusanT's Epitope-specific Immunotherapy For Celiac Disease Informs Potential Of Vaccines Against Other Autoimmune Diseases 78
Sep 05, 2012: Alvine Pharma's ALV003 Receives Fast Track Designation From FDA For Treatment Of Celiac Disease 79
Appendix 81
Methodology 81
Coverage 81
Secondary Research 81
Primary Research 81
Expert Panel Validation 81
Contact Us 81
Disclaimer 82

List of Tables

Number of Products under Development for Celiac Disease, H2 2016 10
Number of Products under Development for Celiac Disease - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Development, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Celiac Disease - Pipeline by Amgen Inc., H2 2016 19
Celiac Disease - Pipeline by Amyra Biotech AG, H2 2016 20
Celiac Disease - Pipeline by Avaxia Biologics, Inc., H2 2016 21
Celiac Disease - Pipeline by Calypso Biotech SA, H2 2016 22
Celiac Disease - Pipeline by enGene, Inc, H2 2016 23
Celiac Disease - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 24
Celiac Disease - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 25
Celiac Disease - Pipeline by ImmusanT, Inc., H2 2016 26
Celiac Disease - Pipeline by Innovate Biopharmaceuticals, Inc., H2 2016 27
Celiac Disease - Pipeline by Intrexon Corporation, H2 2016 28
Celiac Disease - Pipeline by Sanofi, H2 2016 29
Celiac Disease - Pipeline by Zedira GmbH, H2 2016 30
Assessment by Monotherapy Products, H2 2016 31
Number of Products by Stage and Target, H2 2016 33
Number of Products by Stage and Mechanism of Action, H2 2016 35
Number of Products by Stage and Route of Administration, H2 2016 37
Number of Products by Stage and Molecule Type, H2 2016 39
Celiac Disease - Dormant Projects, H2 2016 68